LightNews — News, ranked by scholars

From next-gen EGFR drugs to AI, Korean firms gear up for WCLC Seoul

September 12, 2026 at 11:00 PM

Cecelia Care ♥️😷💉💊

@ceceliacare.bsky.social

"From next-gen EGFR drugs to AI, Korean firms gear up for WCLC Seoul"

#medsky #healthcare #hospice #healthpolicy #homehealth

Korean pharmaceutical, biotech and medical AI companies will unveil a broad range of lung cancer research at the World Conference on Lung Cancer (WCLC), which returns to Seoul for the first time in 19 years.The presentations will spotlight EGFR- and HER2-targeted therapies, novel immunotherapies and

www.koreabiomed.com

September 10, 2026 at 12:00 AM

Nature Reviews Cancer

@natrevcancer.nature.com

#Comment🚨
Swanton&Co @charlesswanton.bsky.social highlight the histories of EGFR, HER2, CDK4/6 and RAS, and discusses how sustained investment in discovery science continues to generate clinical benefit through new drugs, indications and treatment combinations.
📖⬇️

The long return on discovery science in cancer therapeutics - Nature Reviews Cancer

Many advances in cancer treatment depend on discoveries made decades earlier. In this Comment, Murphy et al. discuss the histories of EGFR, HER2, CDK4/6 and RAS, highlighting how long translation can take and how clinical benefit can continue to accumulate as more effective drugs are developed, used in earlier disease settings and combined with existing treatments.

dlvr.it

September 9, 2026 at 3:42 PM

Helen

@prairieisle.bsky.social

Not sure what your oncologist has told you about treatments but here is a link to the Yale vaccine that has is working for dogs with osteosarcoma. therajan.com/joomla/ Trial still going and there are approved clinics throughout the US

Therajan - Canine EGFR/HER2 Peptide Cancer Immunotherapeutic

TheraJan, LLC produces an experimental canine EGFR/HER2 peptide immunotherapeutic. For supervised use by licensed veterinary oncologists. Not yet USDA approved.

therajan.com

September 7, 2026 at 10:58 AM

Shicheng Guo

@shihcheng.bsky.social

New single-particle tracking reveals EGFR, HER2, and HER3 dimerization dynamics; oncogenic mutations cause stable, ligand-independent dimers. Exciting potential for targeted therapies! PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky #Pharmsky #RNA 🧪

https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5

Exploring the Yale Vaccine: A New Hope for Canine Cancer Treatment

September 7, 2026 at 9:00 AM

MotherofCorgs

@motherofcardigans.bsky.social

And here’s an overview of the study: www.ccralliance.org/post/egfr-he...

Professor Mark Mamula (Yale University) provides an update on the EGFR/HER2 "Yale" vaccine cancer treatment for dogs. This immunotherapy targets EGFR and HER2 proteins and has demonstrated promising r...

www.ccralliance.org

September 5, 2026 at 1:05 AM

MotherofCorgs

@motherofcardigans.bsky.social

The thought is that the tumor over-expresses mutations in EGFR and HER2 and they can train their immune system to attack cells with those mutations. There are limited locations that are administering and you have to apply to be accepted into the trial.

September 5, 2026 at 12:56 AM

Shicheng Guo

@shihcheng.bsky.social

Track the dimerization dynamics of EGFR, HER2, and HER3 in live cells! Long-term SPT reveals that oncogenic EGFR mutations stabilize dimers independently of ligands, reshaping receptor interactions. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪

https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5

The long return on discovery science in cancer therapeutics - Nature Reviews Cancer

September 1, 2026 at 3:00 AM

Nicolas Robine 🇪🇺🇫🇷🇺🇸

@nicorobine.bsky.social

"The long return on discovery science in cancer therapeutics" by Cian Murphy, Samuel Hume and @charlesswanton.bsky.social
www.nature.com/articles/s41...

Many advances in cancer treatment depend on discoveries made decades earlier. In this Comment, Murphy et al. discuss the histories of EGFR, HER2, CDK4/6 and RAS, highlighting how long translation can ...

www.nature.com

August 31, 2026 at 2:16 PM

Nature Reviews Cancer

@natrevcancer.nature.com

The long return on discovery science in cancer therapeutics

Nature Reviews Cancer, Published online: 28 August 2026; doi:10.1038/s41568-026-00978-0Many advances in cancer treatment depend on discoveries made decades earlier. In this Comment, Murphy et al. discuss the histories of EGFR, HER2, CDK4/6 and RAS, highlighting how long translation can take and how clinical benefit can continue to accumulate as more effective drugs are developed, used in earlier disease settings and combined with existing treatments.

dlvr.it

August 28, 2026 at 10:09 AM

ipharmaservices.bsky.social

@ipharmaservices.bsky.social

DESTINY-Lung04: #Enhertu melhorou a PFS vs. terapia de 1ª linha no NSCLC não escamoso avançado com mutação HER2. Uma opção direcionada de 1ª linha da AstraZeneca (#$AZN ) & #DaiichiSankyo ipharmacenter.com/post/astraze...
#Cancer #Oncologia #CancerDePulmao #ESMO26 #OncoTwitter #OncoAlert

AstraZeneca–Daiichi Sankyo’s Enhertu Wins DESTINY-Lung04; HUTCHMED’s Tagrisso–Orpathys Pair Wins SAFFRON in MET-Selected EGFR NSCLC

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

AstraZeneca–Daiichi Sankyo’s Enhertu Wins DESTINY-Lung04; HUTCHMED’s Tagrisso–Orpathys Pair Wins SAFFRON in MET-Selected EGFR NSCLC

August 17, 2026 at 3:00 PM

ipharmaservices.bsky.social

@ipharmaservices.bsky.social

DESTINY-Lung04: #Enhertu ha migliorato la PFS rispetto alla terapia di 1a linea nel NSCLC non squamoso avanzato con mutazione HER2. Un'opzione mirata di 1a linea da AstraZeneca (#$AZN) e #DaiichiSankyo ipharmacenter.com/post/astraze...
#Cancro #Oncologia #ESMO26 #OncoTwitter #OncoAlert

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

AstraZeneca–Daiichi Sankyo’s Enhertu Wins DESTINY-Lung04; HUTCHMED’s Tagrisso–Orpathys Pair Wins SAFFRON in MET-Selected EGFR NSCLC

August 17, 2026 at 3:00 PM

ipharmaservices.bsky.social

@ipharmaservices.bsky.social

DESTINY-Lung04: #Enhertu verbesserte das PFS vs. 1L-Therapie bei HER2-mutiertem, fortgeschrittenem nicht-kleinzelligem NSCLC. Eine zielgerichtete 1L-Option von AstraZeneca (NYSE #$AZN) & #DaiichiSankyo ipharmacenter.com/post/astraze...
#Krebs #Onkologie #Lungenkrebs #ESMO26 #OncoTwitter #OncoAlert

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

AstraZeneca–Daiichi Sankyo’s Enhertu Wins DESTINY-Lung04; HUTCHMED’s Tagrisso–Orpathys Pair Wins SAFFRON in MET-Selected EGFR NSCLC

August 17, 2026 at 2:59 PM

ipharmaservices.bsky.social

@ipharmaservices.bsky.social

DESTINY-Lung04: #Enhertu mejoró la PFS frente a la terapia de 1.ª línea en NSCLC no escamoso avanzado con mutación HER2. Una opción dirigida de 1.ª línea de AstraZeneca (#$AZN) y #DaiichiSankyo ipharmacenter.com/post/astraze... #Oncologia #CancerDePulmon #ESMO26 #OncoTwitter #OncoAlert

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5

August 17, 2026 at 2:58 PM

cancergrace

@cancergrace.bsky.social

Sesión de preguntas y respuestas con el Dr. Luis E Raez , Daniel Rosas y Ana Velázquez Mañana, MD MSc FASCO (Velazquez Manana)

"¿Cómo prevé que evolucione el panorama del tratamiento en los próximos cinco años?"

#CáncerDePulmón #EGFR #HER2 #NSCLC #GRACE

August 15, 2026 at 4:04 PM

PharmSolidForms

@pharmsolidforms.bsky.social

Crystal Engineering of Diarylhydrazone Scaffolds: A Combined X-ray Diffraction, in vitro Cytotoxicity Assays, and Molecular Docking Approach for Dual EGFR/HER2 Inhibition https://www.sciencedirect.com/science/article/pii/S0022286026020843 #CrystalEngineering

August 14, 2026 at 9:28 AM

Shicheng Guo

@shihcheng.bsky.social

Study reveals long-term tracking of EGFR, HER2, and HER3 shows oncogenic mutations lead to stable dimerization, disrupting normal activation dynamics. 3 receptors, 1 technique! PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky #Pharmsky #RNA #ASHG 🧪